Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRABEPIO: Trabectedin and Pioglitazone in Liposarcoma
NCT04794127Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pioglitazone in Liposarcoma (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Objective Response at 24 months. Started Feb 2022; status: completed.
02
Drugs
pioglitazone
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NCT04794127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794127.